Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is PulmOne's primary product offering?
- PulmOne's primary product is the MiniBox, a desktop device for measuring lung volume and spirometry. The company also offers the MiniBox+, which includes a diffusing capacity (DLCO) module for a complete pulmonary function testing solution.
- When was PulmOne founded?
- PulmOne was founded in March 2006.
- What regulatory clearances has PulmOne received for its products?
- PulmOne has received FDA 510k clearance and a CE mark for its first product, enabling sales in various locations.
- What is the total amount of funding PulmOne has raised?
- PulmOne has raised a total of $13,709,406 across multiple funding rounds. For a full financing history, please refer to startupim.
- Which investors have participated in PulmOne's funding rounds?
- OurCrowd has been a consistent investor in PulmOne's Series A and Convertible Debt rounds. Alpha LTI also participated as a lead investor in a Convertible Debt round in December 2021.
- Where are PulmOne's main offices located?
- PulmOne's headquarters are in Ra'anana, Israel, and they also have an office in New York, USA.
- What is the employee count for PulmOne?
- PulmOne has 53 employees, falling within the 51-200 employee range.
- What was PulmOne's most recent funding round?
- PulmOne's most recent funding round was a Convertible Debt round in March 2022, which raised $4,000,000.
- What is the purpose of PulmOne's MiniBox+ system?
- The MiniBox+ system from PulmOne expands on the MiniBox's spirometry and lung volume measurement capabilities by adding a diffusing capacity (DLCO) module, providing a comprehensive solution for pulmonary function testing.